Grazia Cirillo

Grazia Cirillo

Auto-generated profile, based on publicly available information

Grazia Cirillo

Department of Woman, Child and of General and Specialized Surgery University of the Study of Campania “Luigi Vanvitelli” Via Luigi De Crecchio 2 Naples Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2004 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
NSNicola Santoro
Nicola Santoro
EGEmanuele Miraglia del Giudice
Emanuele Miraglia del Giudice
GCGrazia Cirillo
Grazia Cirillo
PRPaolo Raimondo
Paolo Raimondo
ICIvana Corsi
Ivana Corsi
LPLaura Perrone
Laura Perrone
Lines of evidence show a role of the melanocortinergic system in the regulation of glucose metabolism in obese subjects. The aim of this study was to investigate the influence of proopiomelanocortin (POMC) in the variability of insulin levels in early-onset obesity. To address this issue, an association study using a 9-bp insertional polymorphism, AGC AGC GGC, between nucleotides 6979 and 6998 of the POMC gene, was performed in 380 (185 girls) Italian obese children and adolescents. Allelic frequencies were comparable in our patients (0.053) and in 300 lean controls of Mediterranean descent (0.045). Interestingly, we showed that this polymorphism, in the obese patients, was associated with differences in fasting insulin levels; this finding persisted after correction for age, sex, and pubertal stage. Heterozygotes had 24% higher mean insulin levels than those homozygous for the wild allele and showed a stronger correlation between insulin and body mass index (P < 0.001). These findings support the hypothesis that the melanocortin pathway may modulate glucose metabolism in obese subjects and suggest that this common POMC variant may be involved in the natural history of polygenic obesity in late adolescence and adulthood, contributing to the link between type 2 diabetes and obesity.

19 December 2023 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
FAFrancesca Aiello
Francesca Aiello
SPS. Palumbo
S. Palumbo
GCG. Cirillo
G. Cirillo
GTGianluca Tornese
Gianluca Tornese
DFDaniela Fava
Daniela Fava
AGAnna Grandone
Anna Grandone

28 July 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ECEmily Cottrell
Emily Cottrell
AMAvinaash Vickram Maharaj
Avinaash Vickram Maharaj
JWJack Williams
Jack Williams
SCSumana Chatterjee
Sumana Chatterjee
GCGrazia Cirillo
Grazia Cirillo
HSHelen L Storr
Helen L Storr
Context Severe forms of Growth Hormone Insensitivity (GHI) are characterized by extreme short stature, dysmorphism and metabolic anomalies. Objective Identification of the genetic cause of growth failure in 3 ‘classical’ GHI subjects. Design A novel intronic GHR variant was identified, and in vitro splicing assays confirmed aberrant splicing. A 6Ω pseudoexon GHR vector and patient fibroblast analysis assessed the consequences of the novel pseudoexon inclusion and the impact on GHR function. Results We identified a novel homozygous intronic GHR variant (g.5:42700940T>G, c.618 + 836T> G), 44bp downstream of the previously recognized intronic 6Ψ GHR pseudoexon mutation in the index patient. Two siblings also harbored the novel intronic 6Ω pseudoexon GHR variant in compound heterozygosity with the known GHR c.181C>T (R43X) mutation. In vitro splicing analysis confirmed inclusion of a 151bp mutant 6Ω pseudoexon not identified in wild-type constructs. Inclusion of the 6Ω pseudoexon causes a frameshift resulting in a non-functional truncated GHR lacking the transmembrane and intracellular domains. The truncated 6Ω pseudoexon protein demonstrated extracellular accumulation and diminished activation of STAT5B signaling following growth hormone stimulation. Conclusion Novel GHR 6Ω pseudoexon inclusion results in loss of GHR function consistent with a severe GHI phenotype. This represents a novel mechanism of Laron syndrome and is the first deep intronic variant identified causing severe postnatal growth failure. The 2 kindreds originate from the same town in Campania, Southern Italy, implying common ancestry. Our findings highlight the importance of studying variation in deep intronic regions as a cause of monogenic disorders.

30 December 2025 in Obesity and Endocrinology
Verified
Journal Article
Open access
GUGiuseppina Rosaria Umano
Giuseppina Rosaria Umano
GCGrazia Cirillo
Grazia Cirillo
ASAnna Di Sessa
Anna Di Sessa
RDRaffaella D’aUsilio
Raffaella D’aUsilio
FGFlavia Guarino
Flavia Guarino
EGEmanuele Miraglia del Giudice
Emanuele Miraglia del Giudice
Objective: A central challenge in clinical genetics lies in the precise interpretation of identified genetic variants and the effective communication of these findings to both patients and healthcare providers. Variability in the management of variant reclassifications, coupled with the absence of standardized guidelines for reevaluation, reanalysis, and the return of variant information, has introduced significant complexities into clinical practice. Although empirical studies have begun to address these issues, the scope and implications of this body of research remain insufficiently defined. Methods: A systematic literature review was undertaken to examine research on variant reclassification within medical genetics in the last 10 years (until October 2025). Out of 582 unique records screened, 39 studies met inclusion criteria. These articles provide insights into the frequency and outcomes of variant reclassification. Results: The included studies reported a wide rate of variant reclassification (from 3.6% to 83.6%). Nineteen studies (48.7%) focused on variants of uncertain significance (VUS), whereas the others included all variant types. The main fields were oncology and cardiology, only one study evaluated reclassification in patients living with obesity. Reclassification methods included literature review, functional studies, in silico prediction of pathogenicity, segregation analysis, and use of machine learning tools. Conclusions: Several ongoing studies on variant reclassification have retrospectively applied established classification guidelines to previously reported variants, illustrating the potential volume of successful reclassifications achievable through routine reinterpretation and reanalysis. Identified research gaps include the limited understanding of the practices especially in the field of endocrinology and the need for structured deliberative processes to foster consensus on recontact and reclassification protocols.

1 January 2026 in Case Reports in Pediatrics
Verified
Journal Article
Open access
PDF file
VCValeria Chirico
Valeria Chirico
FCFabiola Cassaro
Fabiola Cassaro
SSSerena Sbilordo
Serena Sbilordo
ALAntonio Lacquaniti
Antonio Lacquaniti
LSLorena Silipigni
Lorena Silipigni
RCRoberto Chimenz
Roberto Chimenz
Background: Congenital nephrogenic diabetes insipidus (CNDI) is a rare disorder of renal water handling, often presenting in early infancy with severe polyuria and hypernatremia. Differentiating CNDI from central diabetes insipidus (CDI) remains challenging, and delayed identification may result in inappropriate therapy, leading to adverse growth and neurodevelopmental outcomes. Case Presentation: We present the case of an 8‐month‐old male infant with a history of suspected CDI since birth. He was treated with desmopressin (dDAVP) without clinical benefit. The absence of the posterior pituitary bright spot at magnetic resonance imaging supported the CDI diagnosis. Considering persistent polyuria with recurrent episodes of hypernatremia and low urine osmolality, a diagnosis of CNDI was proposed, and plasma copeptin (CP) levels were determined. Measurement of CP showed markedly increased concentrations, suggesting renal tubular resistance to vasopressin. dDAVP therapy was discontinued and patient’s management was adjusted to include hydrochlorothiazide therapy and a high‐calorie diet restricted in sodium and protein. The patient showed progressive clinical improvement with reduction of polyuria and stabilization of serum sodium levels, although linear growth delay persisted. A final diagnosis of CNDI was confirmed by molecular analysis that identified rare compound heterozygous variants in the AQP2 gene, c.85G > A variant (maternal) and c.553C > G (paternal). Conclusions: This case highlights the diagnostic pitfalls of CNDI in infancy and underscores the pivotal role of early CP assessment and molecular genetic testing in distinguishing CNDI from CDI. Prompt recognition of CNDI is essential to avoid ineffective dDAVP therapy and to initiate a targeted multidisciplinary approach. Rare AQP2 mutations further expand the genotypic spectrum of CNDI and emphasize the need for heightened clinical awareness and early referral to specialized centers.